Dissecting the protective IgG anti-malondialdehyde-LDL (MDA-LDL) antibody response in a substudy of the Anglo Scandinavian Cardiac Outcomes Trial (ASCOT)
Background: We had previously demonstrated a significant correlation between higher levels of total IgG anti MDA-LDL antibodies and protection from cardiovascular events. In this subsequent study, we aimed to dissect this autoantibody profile to examine the relationship of two predominant IgG isotypes against MDA-LDL in the same population. Methods: We included ASCOT subjects without diabetes and normal cholesterol. Total IgG, IgG1 and IgG3 antibodies against MDA-LDL were measured by ELISA at baseline and after one year on atorvastatin (10 mg daily;n=100) or placebo (n=100). Cardiac risk factors including CRP were measured at baseline and one year. Clinical follow-up was for a median of 5 years. Results: Total IgG anti-MDA-LDL levels were strongly correlated with a protection from cardiovascular events (log rank test for trend = 0.03; HR = 0.33 [0.13, 0.85]; p = 0.02 in an unadjusted Cox model). This was not attenuated by further adjustment for Framingham CVD score + baseline CRP (adjusted HR = 0.35 [0.13, 0.96]; p=0.04). There was no correlation with baseline LDL, HDL, treatment with statins or CRP. We found no association between anti-MDA-LDL IgG3 or IgG1 levels and cardiovascular events. IgG3 levels were positively correlated with HDL (r=0.21,p=0.004), and IgG1 levels positively correlated with HDL (r=0.178,p= 0.01) and negatively correlated with LDL (r=-0.17,p=0.02). Both anti-MDA-LDL IgG3, and IgG1 levels were not affected by treatment with statins for one year, despite a marked effect on LDL (1.44mol/litre reduction, p<0.001, 95% CI 1.31- 1.58). There was a wide-scatter distribution of IgG1 anti-MDA-LDL levels which appeared to be in a 2-tiered distribution. Conclusion: Levels of these isotype subgroups did not separately account for the protective effect of total IgG and MDA-LDL antibodies, follows different distribution patterns, and is correlated with other biomarkers of cardiovascular disease.